Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This Phase 4 study is being performed to examine the effects of Acthar for the indicated use
of treatment of SLE. This study will enroll patients with steroid-dependent, persistently
active SLE with arthritic and/or cutaneous involvement.
The study will involve two periods: an 8-week double-blind period, to provide
placebo-controlled safety, efficacy, and pharmacodynamic data, and an optional open-label
period, to examine the prolonged effects of Acthar maintenance.